Share Price and Basic Stock Data
Last Updated: November 19, 2025, 9:34 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
JHS Svendgaard Laboratories Ltd operates in the personal care industry and has faced a challenging revenue environment recently. The company’s reported sales for the fiscal year ending March 2025 stood at ₹92 Cr, a decline from ₹94 Cr in the previous year. Over the past few quarters, sales have fluctuated, with a high of ₹24.48 Cr in June 2024 and a low of ₹15.90 Cr in June 2023. The company’s sales trajectory indicates volatility, with quarterly revenues indicating seasonal or operational challenges. The trailing twelve months (TTM) revenue is ₹91 Cr, reflecting a slight improvement from the previous year but still below the peak levels recorded in earlier years, such as ₹140 Cr in FY 2018. This inconsistency in revenue generation poses a question about the company’s market positioning and operational strategies in a competitive personal care landscape.
Profitability and Efficiency Metrics
JHS Svendgaard Laboratories has reported continued challenges in profitability, with a net profit of ₹-20 Cr for FY 2025, a notable deterioration from ₹-18 Cr in FY 2024. The company’s operating profit margin (OPM) has fluctuated, recording a low of -21.37% in March 2025, indicating significant operational inefficiencies. The interest coverage ratio (ICR) stood at -2.01x, underscoring difficulties in meeting interest obligations. The company has also reported negative return on equity (ROE) of -11.43% and return on capital employed (ROCE) of -5.14% for FY 2025, suggesting insufficient returns on shareholder investments and capital employed. The operating profit consistently dipped into negative territory, particularly evident in the March 2023 quarter, where it stood at ₹-9 Cr. These metrics highlight critical challenges in managing costs and achieving profitability.
Balance Sheet Strength and Financial Ratios
JHS Svendgaard’s balance sheet reflects a cautious financial posture with total borrowings of ₹6 Cr against total assets of ₹204 Cr for FY 2025. The company has maintained a low debt-to-equity ratio of 0.02, indicating minimal leverage and a conservative approach to financing. The company’s reserves have decreased to ₹87 Cr from ₹91 Cr in the previous year, which raises concerns about retained earnings and overall financial health. The current ratio of 2.18 indicates a solid liquidity position, suggesting the company can cover its short-term liabilities. However, the price-to-book value (P/BV) ratio is low at 0.55x, which may imply undervaluation in the market or a lack of investor confidence in growth prospects. Overall, while the balance sheet shows some strengths in liquidity and low debt levels, the declining reserves and profitability metrics raise red flags.
Shareholding Pattern and Investor Confidence
The shareholding pattern of JHS Svendgaard Laboratories indicates a diverse ownership structure. Promoters hold 34.56% of the shares as of March 2025, a decline from 42.23% in December 2022, suggesting a potential reduction in promoter confidence or a shift in strategy. Foreign institutional investors (FIIs) own a mere 1.57%, while domestic institutional investors (DIIs) have recently entered with 0% in early 2023, increasing to 0.00% by March 2025. Public ownership is significant at 63.87%, reflecting a broad base of retail investors. The total number of shareholders has decreased to 25,007, down from 24,308 in December 2022. This declining trend in shareholder numbers could indicate waning investor interest or dissatisfaction with the company’s performance and outlook.
Outlook, Risks, and Final Insight
The outlook for JHS Svendgaard Laboratories appears uncertain, primarily due to persistent profitability challenges and declining sales trends. Key risks include the company’s inability to stabilize revenues and improve operational efficiency, as evidenced by negative OPM and net profit figures. Additionally, the declining promoter shareholding may reflect underlying issues that could affect investor confidence. On the positive side, the company maintains a low debt level and reasonable liquidity, which could provide a buffer for strategic investments or operational restructuring. Moving forward, the company must focus on enhancing its operational efficiencies, improving profitability, and regaining investor confidence to navigate the challenging personal care market successfully. Failure to address these issues may result in continued underperformance and potential market exit scenarios.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of JHS Svendgaard Laboratories Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Honasa Consumer Ltd | 9,554 Cr. | 294 | 334/190 | 76.8 | 38.8 | 0.00 % | 7.44 % | 5.51 % | 10.0 |
| Ambica Agarbathies Aroma & Industries Ltd | 43.6 Cr. | 25.5 | 37.0/23.3 | 85.4 | 65.2 | 0.00 % | 7.49 % | 0.45 % | 10.0 |
| Ador Multi Products Ltd | 105 Cr. | 110 | 119/23.4 | 32.5 | 0.00 % | 11.4 % | 3.09 % | 10.0 | |
| Kaya Ltd | 609 Cr. | 400 | 488/204 | 60.9 | 0.00 % | 2.50 % | % | 10.0 | |
| Jyothy Labs Ltd | 11,318 Cr. | 308 | 433/268 | 30.9 | 55.8 | 1.14 % | 24.6 % | 19.0 % | 1.00 |
| Industry Average | 71,671.00 Cr | 1,928.56 | 57.12 | 112.44 | 0.74% | 29.21% | 23.91% | 4.94 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 21.31 | 21.05 | 22.19 | 21.72 | 15.90 | 18.93 | 14.30 | 21.66 | 24.48 | 19.68 | 22.66 | 25.17 | 23.45 |
| Expenses | 22.77 | 23.02 | 24.41 | 25.28 | 18.02 | 18.52 | 14.36 | 20.82 | 22.51 | 20.52 | 22.41 | 30.55 | 21.79 |
| Operating Profit | -1.46 | -1.97 | -2.22 | -3.56 | -2.12 | 0.41 | -0.06 | 0.84 | 1.97 | -0.84 | 0.25 | -5.38 | 1.66 |
| OPM % | -6.85% | -9.36% | -10.00% | -16.39% | -13.33% | 2.17% | -0.42% | 3.88% | 8.05% | -4.27% | 1.10% | -21.37% | 7.08% |
| Other Income | 1.48 | 2.52 | 0.94 | -11.54 | 0.41 | 0.20 | 2.34 | 1.37 | 0.32 | 0.86 | 0.27 | -1.44 | 1.00 |
| Interest | 0.68 | 0.12 | 0.16 | 0.11 | 0.13 | 0.10 | 0.11 | 0.13 | 0.12 | 0.11 | 0.13 | 0.21 | 0.16 |
| Depreciation | 1.70 | 1.49 | 1.46 | 1.61 | 1.32 | 1.50 | 1.63 | 1.90 | 1.97 | 1.98 | 1.97 | 2.02 | 1.88 |
| Profit before tax | -2.36 | -1.06 | -2.90 | -16.82 | -3.16 | -0.99 | 0.54 | 0.18 | 0.20 | -2.07 | -1.58 | -9.05 | 0.62 |
| Tax % | 75.85% | -13.21% | -4.83% | -36.39% | -18.35% | -26.26% | 100.00% | 516.67% | 415.00% | 398.07% | 15.82% | -23.09% | -69.35% |
| Net Profit | -4.16 | -0.92 | -2.76 | -10.71 | -2.59 | -0.73 | 0.01 | -0.75 | -0.63 | -10.32 | -1.84 | -6.96 | 1.06 |
| EPS in Rs | -0.59 | -0.14 | -0.43 | -1.65 | -0.40 | -0.09 | 0.00 | -0.10 | -0.08 | -1.21 | -0.21 | -0.81 | 0.12 |
Last Updated: August 20, 2025, 8:40 am
Below is a detailed analysis of the quarterly data for JHS Svendgaard Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 23.45 Cr.. The value appears to be declining and may need further review. It has decreased from 25.17 Cr. (Mar 2025) to 23.45 Cr., marking a decrease of 1.72 Cr..
- For Expenses, as of Jun 2025, the value is 21.79 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 30.55 Cr. (Mar 2025) to 21.79 Cr., marking a decrease of 8.76 Cr..
- For Operating Profit, as of Jun 2025, the value is 1.66 Cr.. The value appears strong and on an upward trend. It has increased from -5.38 Cr. (Mar 2025) to 1.66 Cr., marking an increase of 7.04 Cr..
- For OPM %, as of Jun 2025, the value is 7.08%. The value appears strong and on an upward trend. It has increased from -21.37% (Mar 2025) to 7.08%, marking an increase of 28.45%.
- For Other Income, as of Jun 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from -1.44 Cr. (Mar 2025) to 1.00 Cr., marking an increase of 2.44 Cr..
- For Interest, as of Jun 2025, the value is 0.16 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.21 Cr. (Mar 2025) to 0.16 Cr., marking a decrease of 0.05 Cr..
- For Depreciation, as of Jun 2025, the value is 1.88 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.02 Cr. (Mar 2025) to 1.88 Cr., marking a decrease of 0.14 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.62 Cr.. The value appears strong and on an upward trend. It has increased from -9.05 Cr. (Mar 2025) to 0.62 Cr., marking an increase of 9.67 Cr..
- For Tax %, as of Jun 2025, the value is -69.35%. The value appears to be improving (decreasing) as expected. It has decreased from -23.09% (Mar 2025) to -69.35%, marking a decrease of 46.26%.
- For Net Profit, as of Jun 2025, the value is 1.06 Cr.. The value appears strong and on an upward trend. It has increased from -6.96 Cr. (Mar 2025) to 1.06 Cr., marking an increase of 8.02 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.12. The value appears strong and on an upward trend. It has increased from -0.81 (Mar 2025) to 0.12, marking an increase of 0.93.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:04 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 35 | 55 | 100 | 104 | 140 | 124 | 139 | 101 | 86 | 85 | 71 | 92 | 91 |
| Expenses | 39 | 59 | 93 | 92 | 126 | 124 | 137 | 99 | 87 | 94 | 72 | 96 | 95 |
| Operating Profit | -4 | -4 | 7 | 12 | 14 | 0 | 2 | 2 | -1 | -9 | -1 | -4 | -4 |
| OPM % | -11% | -7% | 7% | 11% | 10% | 0% | 1% | 2% | -1% | -11% | -1% | -4% | -5% |
| Other Income | -3 | -6 | -17 | 0 | 32 | 6 | 3 | 7 | 9 | -7 | 4 | 0 | 1 |
| Interest | 14 | 0 | 0 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 0 | 1 | 1 |
| Depreciation | 15 | 12 | 10 | 6 | 7 | 7 | 9 | 7 | 7 | 6 | 6 | 8 | 8 |
| Profit before tax | -35 | -22 | -22 | 5 | 38 | -2 | -6 | 1 | 0 | -23 | -3 | -13 | -12 |
| Tax % | -18% | 0% | 0% | -327% | 32% | -19% | -17% | -39% | 4,000% | -24% | 18% | 58% | |
| Net Profit | -29 | -22 | -22 | 22 | 26 | -2 | -5 | 1 | -4 | -18 | -4 | -20 | -18 |
| EPS in Rs | -11.95 | -9.20 | -5.76 | 4.98 | 4.29 | -0.11 | -0.33 | 0.19 | -0.62 | 0.62 | -0.52 | -2.31 | -2.11 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 24.14% | 0.00% | 200.00% | 18.18% | -107.69% | -150.00% | 120.00% | -500.00% | -350.00% | 77.78% | -400.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -24.14% | 200.00% | -181.82% | -125.87% | -42.31% | 270.00% | -620.00% | 150.00% | 427.78% | -477.78% |
JHS Svendgaard Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | -8% |
| 3 Years: | 2% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -624% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -9% |
| 3 Years: | -23% |
| 1 Year: | -61% |
| Return on Equity | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| Last Year: | -11% |
Last Updated: September 5, 2025, 8:15 am
Balance Sheet
Last Updated: September 10, 2025, 1:54 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 24 | 24 | 38 | 44 | 61 | 61 | 61 | 64 | 65 | 78 | 78 | 86 |
| Reserves | 38 | 96 | 63 | 90 | 113 | 116 | 117 | 124 | 121 | 95 | 91 | 87 |
| Borrowings | 54 | 19 | 3 | 2 | 2 | 7 | 9 | 7 | 6 | 3 | 5 | 6 |
| Other Liabilities | 74 | 33 | 19 | 19 | 32 | 39 | 55 | 33 | 30 | 52 | 22 | 25 |
| Total Liabilities | 190 | 171 | 122 | 155 | 208 | 223 | 241 | 228 | 222 | 228 | 197 | 204 |
| Fixed Assets | 121 | 108 | 65 | 65 | 71 | 71 | 66 | 63 | 59 | 65 | 90 | 90 |
| CWIP | 0 | 0 | 1 | 1 | 1 | 5 | 7 | 9 | 20 | 9 | 1 | 0 |
| Investments | 0 | 0 | 0 | 1 | 18 | 10 | 6 | 2 | 4 | 3 | 3 | 4 |
| Other Assets | 70 | 63 | 57 | 89 | 118 | 137 | 163 | 154 | 140 | 152 | 102 | 110 |
| Total Assets | 190 | 171 | 122 | 155 | 208 | 223 | 241 | 228 | 222 | 228 | 197 | 204 |
Below is a detailed analysis of the balance sheet data for JHS Svendgaard Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 86.00 Cr.. The value appears strong and on an upward trend. It has increased from 78.00 Cr. (Mar 2024) to 86.00 Cr., marking an increase of 8.00 Cr..
- For Reserves, as of Mar 2025, the value is 87.00 Cr.. The value appears to be declining and may need further review. It has decreased from 91.00 Cr. (Mar 2024) to 87.00 Cr., marking a decrease of 4.00 Cr..
- For Borrowings, as of Mar 2025, the value is 6.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 5.00 Cr. (Mar 2024) to 6.00 Cr., marking an increase of 1.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 25.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 22.00 Cr. (Mar 2024) to 25.00 Cr., marking an increase of 3.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 204.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 197.00 Cr. (Mar 2024) to 204.00 Cr., marking an increase of 7.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 90.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 90.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 1.00 Cr..
- For Investments, as of Mar 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2024) to 4.00 Cr., marking an increase of 1.00 Cr..
- For Other Assets, as of Mar 2025, the value is 110.00 Cr.. The value appears strong and on an upward trend. It has increased from 102.00 Cr. (Mar 2024) to 110.00 Cr., marking an increase of 8.00 Cr..
- For Total Assets, as of Mar 2025, the value is 204.00 Cr.. The value appears strong and on an upward trend. It has increased from 197.00 Cr. (Mar 2024) to 204.00 Cr., marking an increase of 7.00 Cr..
Notably, the Reserves (87.00 Cr.) exceed the Borrowings (6.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -58.00 | -23.00 | 4.00 | 10.00 | 12.00 | -7.00 | -7.00 | -5.00 | -7.00 | -12.00 | -6.00 | -10.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 188 | 167 | 25 | 48 | 111 | 158 | 252 | 213 | 77 | 80 | 66 | 52 |
| Inventory Days | 122 | 94 | 53 | 95 | 65 | 60 | 30 | 97 | 114 | 128 | 176 | 153 |
| Days Payable | 95 | 106 | 67 | 123 | 153 | 134 | 177 | 128 | 130 | 197 | 197 | 141 |
| Cash Conversion Cycle | 215 | 156 | 12 | 19 | 23 | 85 | 105 | 182 | 61 | 11 | 46 | 63 |
| Working Capital Days | -708 | -39 | 58 | 56 | 122 | 173 | 198 | 272 | 217 | 41 | 51 | 48 |
| ROCE % | -10% | -12% | -3% | 5% | 8% | -0% | 4% | 1% | 1% | -2% | -2% | -5% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -2.37 | -0.52 | -2.34 | -0.63 | 0.20 |
| Diluted EPS (Rs.) | -2.37 | -0.52 | -2.34 | -0.63 | 0.20 |
| Cash EPS (Rs.) | -1.38 | 0.29 | -1.43 | 0.42 | 1.33 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 20.18 | 21.67 | 27.78 | 30.05 | 30.74 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 20.18 | 21.67 | 27.78 | 30.05 | 30.74 |
| Revenue From Operations / Share (Rs.) | 10.75 | 9.03 | 14.82 | 13.29 | 15.65 |
| PBDIT / Share (Rs.) | -0.13 | 0.43 | 0.81 | 1.32 | 1.47 |
| PBIT / Share (Rs.) | -1.06 | -0.37 | -0.33 | 0.23 | 0.34 |
| PBT / Share (Rs.) | -1.46 | -0.43 | -3.37 | 0.01 | 0.15 |
| Net Profit / Share (Rs.) | -2.31 | -0.51 | -2.58 | -0.66 | 0.20 |
| NP After MI And SOA / Share (Rs.) | -2.31 | -0.51 | -2.38 | -0.62 | 0.18 |
| PBDIT Margin (%) | -1.23 | 4.77 | 5.50 | 9.91 | 9.39 |
| PBIT Margin (%) | -9.87 | -4.19 | -2.25 | 1.73 | 2.19 |
| PBT Margin (%) | -13.59 | -4.84 | -22.70 | 0.11 | 0.96 |
| Net Profit Margin (%) | -21.46 | -5.73 | -17.43 | -4.97 | 1.33 |
| NP After MI And SOA Margin (%) | -21.46 | -5.73 | -16.07 | -4.69 | 1.18 |
| Return on Networth / Equity (%) | -11.43 | -2.38 | -8.96 | -2.17 | 0.63 |
| Return on Capital Employeed (%) | -5.14 | -1.70 | -1.09 | 0.73 | 1.07 |
| Return On Assets (%) | -9.81 | -2.05 | -6.54 | -1.82 | 0.52 |
| Total Debt / Equity (X) | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 |
| Asset Turnover Ratio (%) | 0.46 | 0.32 | 0.41 | 0.36 | 0.42 |
| Current Ratio (X) | 2.18 | 1.87 | 2.36 | 4.18 | 5.23 |
| Quick Ratio (X) | 1.70 | 1.33 | 2.00 | 3.54 | 4.73 |
| Inventory Turnover Ratio (X) | 7.50 | 3.11 | 4.36 | 5.16 | 8.94 |
| Interest Coverage Ratio (X) | -2.01 | 7.34 | 5.09 | 6.13 | 7.63 |
| Interest Coverage Ratio (Post Tax) (X) | -28.88 | -7.82 | 2.78 | -2.08 | 2.08 |
| Enterprise Value (Cr.) | 81.22 | 121.69 | 70.51 | 136.74 | 117.07 |
| EV / Net Operating Revenue (X) | 0.88 | 1.72 | 0.73 | 1.59 | 1.16 |
| EV / EBITDA (X) | -71.68 | 36.03 | 13.31 | 15.99 | 12.37 |
| MarketCap / Net Operating Revenue (X) | 1.04 | 1.81 | 1.06 | 1.55 | 1.27 |
| Price / BV (X) | 0.55 | 0.75 | 0.59 | 0.71 | 0.68 |
| Price / Net Operating Revenue (X) | 1.04 | 1.81 | 1.06 | 1.55 | 1.27 |
| EarningsYield | -0.20 | -0.03 | -0.15 | -0.03 | 0.01 |
After reviewing the key financial ratios for JHS Svendgaard Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -2.37. This value is below the healthy minimum of 5. It has decreased from -0.52 (Mar 24) to -2.37, marking a decrease of 1.85.
- For Diluted EPS (Rs.), as of Mar 25, the value is -2.37. This value is below the healthy minimum of 5. It has decreased from -0.52 (Mar 24) to -2.37, marking a decrease of 1.85.
- For Cash EPS (Rs.), as of Mar 25, the value is -1.38. This value is below the healthy minimum of 3. It has decreased from 0.29 (Mar 24) to -1.38, marking a decrease of 1.67.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 20.18. It has decreased from 21.67 (Mar 24) to 20.18, marking a decrease of 1.49.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 20.18. It has decreased from 21.67 (Mar 24) to 20.18, marking a decrease of 1.49.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 10.75. It has increased from 9.03 (Mar 24) to 10.75, marking an increase of 1.72.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.13. This value is below the healthy minimum of 2. It has decreased from 0.43 (Mar 24) to -0.13, marking a decrease of 0.56.
- For PBIT / Share (Rs.), as of Mar 25, the value is -1.06. This value is below the healthy minimum of 0. It has decreased from -0.37 (Mar 24) to -1.06, marking a decrease of 0.69.
- For PBT / Share (Rs.), as of Mar 25, the value is -1.46. This value is below the healthy minimum of 0. It has decreased from -0.43 (Mar 24) to -1.46, marking a decrease of 1.03.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -2.31. This value is below the healthy minimum of 2. It has decreased from -0.51 (Mar 24) to -2.31, marking a decrease of 1.80.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -2.31. This value is below the healthy minimum of 2. It has decreased from -0.51 (Mar 24) to -2.31, marking a decrease of 1.80.
- For PBDIT Margin (%), as of Mar 25, the value is -1.23. This value is below the healthy minimum of 10. It has decreased from 4.77 (Mar 24) to -1.23, marking a decrease of 6.00.
- For PBIT Margin (%), as of Mar 25, the value is -9.87. This value is below the healthy minimum of 10. It has decreased from -4.19 (Mar 24) to -9.87, marking a decrease of 5.68.
- For PBT Margin (%), as of Mar 25, the value is -13.59. This value is below the healthy minimum of 10. It has decreased from -4.84 (Mar 24) to -13.59, marking a decrease of 8.75.
- For Net Profit Margin (%), as of Mar 25, the value is -21.46. This value is below the healthy minimum of 5. It has decreased from -5.73 (Mar 24) to -21.46, marking a decrease of 15.73.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -21.46. This value is below the healthy minimum of 8. It has decreased from -5.73 (Mar 24) to -21.46, marking a decrease of 15.73.
- For Return on Networth / Equity (%), as of Mar 25, the value is -11.43. This value is below the healthy minimum of 15. It has decreased from -2.38 (Mar 24) to -11.43, marking a decrease of 9.05.
- For Return on Capital Employeed (%), as of Mar 25, the value is -5.14. This value is below the healthy minimum of 10. It has decreased from -1.70 (Mar 24) to -5.14, marking a decrease of 3.44.
- For Return On Assets (%), as of Mar 25, the value is -9.81. This value is below the healthy minimum of 5. It has decreased from -2.05 (Mar 24) to -9.81, marking a decrease of 7.76.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.46. It has increased from 0.32 (Mar 24) to 0.46, marking an increase of 0.14.
- For Current Ratio (X), as of Mar 25, the value is 2.18. This value is within the healthy range. It has increased from 1.87 (Mar 24) to 2.18, marking an increase of 0.31.
- For Quick Ratio (X), as of Mar 25, the value is 1.70. This value is within the healthy range. It has increased from 1.33 (Mar 24) to 1.70, marking an increase of 0.37.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.50. This value is within the healthy range. It has increased from 3.11 (Mar 24) to 7.50, marking an increase of 4.39.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -2.01. This value is below the healthy minimum of 3. It has decreased from 7.34 (Mar 24) to -2.01, marking a decrease of 9.35.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -28.88. This value is below the healthy minimum of 3. It has decreased from -7.82 (Mar 24) to -28.88, marking a decrease of 21.06.
- For Enterprise Value (Cr.), as of Mar 25, the value is 81.22. It has decreased from 121.69 (Mar 24) to 81.22, marking a decrease of 40.47.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.88. This value is below the healthy minimum of 1. It has decreased from 1.72 (Mar 24) to 0.88, marking a decrease of 0.84.
- For EV / EBITDA (X), as of Mar 25, the value is -71.68. This value is below the healthy minimum of 5. It has decreased from 36.03 (Mar 24) to -71.68, marking a decrease of 107.71.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.04. This value is within the healthy range. It has decreased from 1.81 (Mar 24) to 1.04, marking a decrease of 0.77.
- For Price / BV (X), as of Mar 25, the value is 0.55. This value is below the healthy minimum of 1. It has decreased from 0.75 (Mar 24) to 0.55, marking a decrease of 0.20.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.04. This value is within the healthy range. It has decreased from 1.81 (Mar 24) to 1.04, marking a decrease of 0.77.
- For EarningsYield, as of Mar 25, the value is -0.20. This value is below the healthy minimum of 5. It has decreased from -0.03 (Mar 24) to -0.20, marking a decrease of 0.17.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in JHS Svendgaard Laboratories Ltd:
- Net Profit Margin: -21.46%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -5.14% (Industry Average ROCE: 29.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -11.43% (Industry Average ROE: 23.91%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -28.88
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.7
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 57.12)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -21.46%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Personal Care | Trilokpur Road, Kheri (Kala Amb), Sirmour Dist. Himachal Pradesh 173030 | cs@svendgaard.com http://www.svendgaard.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rajagopal Chakravarthi Venkateish | Chairman & Ind.Director |
| Mr. Nikhil Nanda | Managing & Executive Director |
| Mr. Vinay Mittal | Non Executive Director |
| Mr. Kapil Minocha | Independent Director |
| Mrs. Upma Chawdhry | Independent Woman Director |
FAQ
What is the intrinsic value of JHS Svendgaard Laboratories Ltd?
JHS Svendgaard Laboratories Ltd's intrinsic value (as of 20 November 2025) is 26.83 which is 133.30% higher the current market price of 11.50, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 98.1 Cr. market cap, FY2025-2026 high/low of 25.1/9.90, reserves of ₹87 Cr, and liabilities of 204 Cr.
What is the Market Cap of JHS Svendgaard Laboratories Ltd?
The Market Cap of JHS Svendgaard Laboratories Ltd is 98.1 Cr..
What is the current Stock Price of JHS Svendgaard Laboratories Ltd as on 20 November 2025?
The current stock price of JHS Svendgaard Laboratories Ltd as on 20 November 2025 is 11.5.
What is the High / Low of JHS Svendgaard Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of JHS Svendgaard Laboratories Ltd stocks is 25.1/9.90.
What is the Stock P/E of JHS Svendgaard Laboratories Ltd?
The Stock P/E of JHS Svendgaard Laboratories Ltd is .
What is the Book Value of JHS Svendgaard Laboratories Ltd?
The Book Value of JHS Svendgaard Laboratories Ltd is 20.3.
What is the Dividend Yield of JHS Svendgaard Laboratories Ltd?
The Dividend Yield of JHS Svendgaard Laboratories Ltd is 0.00 %.
What is the ROCE of JHS Svendgaard Laboratories Ltd?
The ROCE of JHS Svendgaard Laboratories Ltd is 5.19 %.
What is the ROE of JHS Svendgaard Laboratories Ltd?
The ROE of JHS Svendgaard Laboratories Ltd is 10.8 %.
What is the Face Value of JHS Svendgaard Laboratories Ltd?
The Face Value of JHS Svendgaard Laboratories Ltd is 10.0.